Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

46.62USD
9 Dec 2016
Change (% chg)

$-0.64 (-1.35%)
Prev Close
$47.26
Open
$46.74
Day's High
$47.42
Day's Low
$46.52
Volume
35,485
Avg. Vol
56,216
52-wk High
$54.70
52-wk Low
$40.74

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Ltd's Promius Pharma receives FDA Approval for Sernivo (betamethasone dipropionate) Spray, 0.05%
Sunday, 7 Feb 2016 10:37pm EST 

Dr.Reddy's Laboratories Ltd:Says that its US subsidiary, Promius PharmaTM, LLC, U.S, has received approval for Sernivo (betamethasone dipropionate) Spray, 0.05% from U.S. Food and Drug Administration (FDA).Say sSernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.Says commercial launch of the product is planned for the coming quarter.  Full Article

Dr.Reddy's Laboratories Ltd receives FDA approval for ZEMBRACE SymTouch injection for acute treatment of migraines in adults
Tuesday, 2 Feb 2016 04:38pm EST 

Dr.Reddy's Laboratories Ltd:Receives FDA approval for ZEMBRACE SymTouch injection for acute treatment of migraines in adults.  Full Article

Dr.Reddy's Laboratories Ltd ays USFDA grants extension till Dec 7 for warning letter response
Wednesday, 25 Nov 2015 05:36pm EST 

Dr.Reddy's Laboratories Ltd:Update on USFDA warning letter.Co in process of preparing response to FDA warning letter.FDA has granted an extension until December 7 for submission of response.  Full Article

Dr.Reddy's Laboratories Ltd slumps; US FDA releases details of warning letter - Reuters
Wednesday, 25 Nov 2015 12:22pm EST 

Dr.Reddy's Laboratories Ltd:Dr Reddy's Laboratories' REDY.NS shares slump as much as 8.3 pct - RTRS.Marks its lowest intraday level since Feb.10 - RTRS.US FDA releases details of warning letter (http://1.usa.gov/1QIDDeg) - RTRS.Warning letter details are stringent in tone and scope - analysts - RTRS.Observations about an "uncontrolled custom QC lab previously unknown to the FDA" and "recurrent violations" are particularly worrisome as they go beyond procedural issues - Citi - RTRS.The content of the warning letter for the three manufacturing sites for Dr Reddy's is strongly worded - CLSA - RTRS.Dr Reddy's response to the warning letter would be crucial, failing which there could be an adverse action (import alert) for these sites - CLS - RTRS.  Full Article

Dr.Reddy's Laboratories Ltd - U.S. court imposes temporary sales ban on Dr Reddy's generic Nexium - Reuters
Tuesday, 10 Nov 2015 05:58am EST 

Dr.Reddy's Laboratories Ltd:Dr Reddy's Laboratories Ltd said on Tuesday it had been temporarily barred by a U.S. court from selling its generic form of blockbuster heartburn drug Nexium in the United States - RTRS.The order was passed by the U.S. district court of Delaware after AstraZeneca, the maker of Nexium, moved a motion objecting to the use of the colour purple in the Dr Reddy's copycat product, the Indian firm said in a statement - RTRS.The temporary restraining order has been imposed "with immediate effect on sales, delivery, transfer, or other disposition" of Dr Reddy's generic Nexium, the company said - RTRS.Dr Reddy's launched its generic Nexium in September after weeks of delay, as it had to shift production to a different plant after the U.S. Food and Drug Administration found quality control lapses at the original site - RTRS.  Full Article

Dr.Reddy's Laboratories Ltd's statement on receipt of warning letter from US FDA
Thursday, 5 Nov 2015 11:40pm EST 

Dr.Reddy's Laboratories Ltd:Acknowledged that it has received a warning letter issued by the US FDA dated Nov. 5, relating to its API manufacturing facilities at Srikakulam and Miryalaguda, as well as oncology formulation manufacturing facility at Duvvada, Visakhapatanam.Says this action follows the earlier inspections of these sites by agency in Nov. 2014, Jan. 2015 and Feb. 2015 respectively.  Full Article

Dr.Reddy's Laboratories Ltd to buy IP rights of Alchemia's fondparinux drug
Monday, 28 Sep 2015 04:38am EDT 

Dr.Reddy's Laboratories Ltd:Announces to buy IP rights of Alchemia's fondaparinux drug for 116 cr Indian Rupees.  Full Article

Dr.Reddy's Laboratories Ltd Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg
Monday, 28 Sep 2015 01:25am EDT 

Dr.Reddy's Laboratories Ltd:Says it has launched ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 mg and 40 mg, a therapeutic equivalent generic version of NEXIUM Delayed-Release Capsules in the US market on September 25, 2015, following the approval by the United States Food & Drug Administration (USFDA).  Full Article

Dr.Reddy's Laboratories Ltd signs commercialization deal with Hatchtech
Monday, 14 Sep 2015 12:31am EDT 

Dr.Reddy's Laboratories Ltd:Announces signing of a commercialization deal with Hatchtech United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.Says the exclusive rights for this product are applicable for the territories of the.  Full Article

PanTheryx and Dr.Reddy's announce an agreement to market PanTheryx's Proprietary Nutritional Intervention for Pediatric Infectious Diarrhea
Tuesday, 8 Sep 2015 09:30pm EDT 

Dr.Reddy's Laboratories Ltd and PanTheryx Inc:Announces a multi-country supply and licensing agreement.The agreement grants the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ (reg), for infectious diarrhea in India, Nepal, Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select LATAM markets.Says Dr. Reddy's will market the product in India and Nepal under the 'Reliqua' brand.  Full Article

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage: